Patents by Inventor Manuel S. Yepes

Manuel S. Yepes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
    Patent number: 7939490
    Abstract: The present invention is directed to compositions and methods for treating cerebral edema and cell death in neurological conditions characterized by disruption of the architecture of the neurovascular unit with increase in the permeability of the NVU, particularly for treating stroke. One aspect of the present invention relates to a composition comprising an agent that interferes with a TWEAK-mediated signaling pathway. Another aspect of the present invention relates to a method of using a composition which comprises an agent that inhibits Fn14 activity or Fn14 expression for the prevention and/or treatment of cerebral edema and cell death occurring in certain neurological conditions such as cerebral ischemia.
    Type: Grant
    Filed: November 8, 2005
    Date of Patent: May 10, 2011
    Assignee: University of Maryland, Baltimore
    Inventors: Jeffrey A. Winkles, Manuel S. Yepes
  • Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein
    Patent number: 7375076
    Abstract: The present invention is a method of reducing vascular permeability in tissue of a subject comprising inhibiting the activity of serine proteinase tissue-type plasminogen activator (tPA). This tPA activity which increases permeability of the tissue in a subject results in edema in the tissue is separate from tPA's thrombolytic activity. The present invention more specifically relates to administering an amount of a tPA inhibitor sufficient to reduce the vascular permeability increasing activity of tPA in a subject. Useful tPA inhibitors for the present method are neuroserpin, mutant neuroserpin, wild-type PAI-1, mutant PAI-1, an antibody that binds to tPA, an antibody that binds to the low-density lipoprotein (LDL) receptor or a low-density lipoprotein (LDL) receptor family antagonist.
    Type: Grant
    Filed: May 20, 2004
    Date of Patent: May 20, 2008
    Assignee: The Regents of The University of Michigan
    Inventors: Daniel A. Lawrence, Manuel S. Yepes, Dudley Strickland